Enterprise Value
42.07M
Cash
40.36M
Avg Qtr Burn
-10.39M
Short % of Float
2.22%
Insider Ownership
2.85%
Institutional Own.
44.98%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EB-101 (COL7A1) Details Recessive dystrophic epidermolysis bullosa | BLA Submission | |
ABO-102 (AAV-based Gene Therapy) Details Mucopolysaccharidosis type IIIA, Rare diseases, Rare genetic disease, Genetic disorder, Mucopolysaccharidoses | Phase 1/2 Update | |
ABO-101 (AAV-based Gene Therapy) Details Rare diseases, Rare genetic disease, Genetic disorder, Mucopolysaccharidoses, Mucopolysaccharidosis type IIIB | Failed Discontinued |